Astellas GU Masterclass: XTANDI

Saturday 12 July 2025, 14:00 - 16:45 KST

Prostate Cancer

Faculty highlights video

Professor Po-Hung Lin, Taiwan

Plenary slides

Welcome and introduction from Chair

Prof. Inkeun Park, South Korea
5 minutes

The Chair provides an overview of the obecjtives and agenda for the meeting

xtandi
Session 1 - The evolving role of ARPIs in mHSPC

Prof. Çağatay Arslan, Turkey
35 minutes

The importance and impact of first treatment choice in mHSPC

xtandi
Session 2 - Management of patients with advanced prostate cancer: The latest APCCC recommendations

Prof. Lisa Horvath, Australia

45 minutes

A discussion of expert recommendations from the APCCC for patients with mHSPC

xtandi
Session 3 - Putting patients at the center: Case studies

Dr Po-Hung Lin, Taiwan

Prof. Chang Gon Kim, South Korea

60 minutes

A discussion of common treatment-related AEs (fatigue and bone health) and management for patients with mHSPC

xtandi
Session 4 - Take-home messages and meeting close

Professor Inkeun Park, South Korea

xtandi

Prescribing Information

Prescribing Information is available for XTANDI® soft capsule 40mg (enzalutamide) here. This promotional meeting is fully sponsored and supported by Astellas, including speaker-related honoraria and production of materials. It is intended for healthcare professionals only.

XTANDI indications:

  • Treatment of patients with mCRPC with asymptomatic or mild symptoms
  • Treatment of patients with mCRPC previously treated with docetaxel
  • Treatment of patients with high-risk nmCRPC
  • Combined with ADT in the treatment of patients with mHSPC
  • Treatment of patients with high-risk BCR nmHSPC

Please refer to the Korean PI for XTANDI® (enzalutamide) via the following QR Code:

XTANDI soft capsule 40mg

XTANDI 40mg

Adverse events should be reported.

For Korea, healthcare professionals are asked to report any suspected adverse reactions to Astellas Pharma Korea. Inc
(Address: 7F Parnas tower, 521, Teheran-ro, Gangnam-gu, Seoul, Republic of Korea; Telephone: +82 10 5254 3389; Email: safety-kr@kr.astellas.com)

ADT, androgen deprivation therapy; AE, adverse event; APCCC, Advanced Prostate Cancer Consensus Conference; ARPI, androgen receptor pathway inhibitor; BCR, biochemical recurrence; mHSPC, metastatic hormone-sensitive prostate cancer; mCRPC, metastatic castration-resistant prostate cancer; nmCRPC, non-metastatic hormone-sensitive prostate cancer.